Damato, A., Iachetta, F., Antonuzzo, L., Nasti, G., Bergamo, F., Bordonaro, R., . . . Pinto, C. (2020). Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018). BMC Cancer.
Citação norma ChicagoDamato, Angela, et al. "Phase II Study On First-line Treatment of NIVolumab in Combination With Folfoxiri/bevacizumab in Patients With Advanced COloRectal Cancer RAS or BRAF Mutated – NIVACOR Trial (GOIRC-03-2018)." BMC Cancer 2020.
MLA引文Damato, Angela, et al. "Phase II Study On First-line Treatment of NIVolumab in Combination With Folfoxiri/bevacizumab in Patients With Advanced COloRectal Cancer RAS or BRAF Mutated – NIVACOR Trial (GOIRC-03-2018)." BMC Cancer 2020.